Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of ac...
Q1 2026
Apr 1, 2026
FY 2025
Mar 31, 2026
Q4 2025
Q3 2025
Dec 3, 2025
Q2 2025
Aug 13, 2025
